|Westminster College, MBA|
John B. Wirthlin joined AlloCure as founding CEO in 2006. Since joining the company, he played a major role in the successful IND filing and execution of the Phase 1 clinical trial targeting acute renal failure.
In June of 2008 Mr. Wirthlin led AlloCure through the closing of a Series A financing with SV Life Sciences and Novo A/S.
Mr. Wirthlin previously worked for Echelon Biosciences where he served as Secretary of the Board, Director of Business Development and Director of Operations. Echelon was acquired by Aeterna Zentaris in 2004.
Prior to joining Echelon, he worked in the financial services and investment banking sector.
Mr. Wirthlin received his MBA from Westminster College with an emphasis on technology commercialization.